Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops carbohydrate-based therapeutics targeting galectin proteins, which are key mediators of biologic and pathologic functions. The company's primary focus is on its lead drug candidate, belapectin (GR-MD-02), which is being evaluated in the NAVIGATE Phase 2b/3 clinical trial for the prevention of esophageal varices in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension. In addition to its liver disease program, Galectin is exploring the potential of its galectin inhibitors in oncology, including combination immunotherapies for advanced melanoma and head and neck squamous cell carcinoma. The company also operates a collaborative joint venture, Galectin Sciences LLC, to develop small organic molecule galectin-3 inhibitors for oral administration. Originally founded in 2000 as Pro-Pharmaceuticals, Inc., the company rebranded to Galectin Therapeutics in 2011.
